Another study using a mouse model of mutant KrasG12D-induced lung cancer showed that suppressing the NRF2 pathway with the chemical inhibitor brusatol enhanced the antitumour efficacy of cisplatin and reduced the tumour burden as well as improving survival [223]. This evidence concerns the gene NFE2L2 and lung carcinoma.